2.1  0.05 (2.44%)		04-20 16:00
Open: 2.03 High: 2.1 Volume: 51,893		Pre. Close: 2.05 Low: 1.98 Market Cap: 21(M)

Short term
Mid term
Targets	6-month :	2.91	1-year :	3.84
Resists	First :	2.49	Second :	3.28
Pivot price	2.01
Supports	First :	1.22	Second :	1.01
MAs	MA(5) :	2.01	MA(20) :	2.18
	MA(100) :	2.41	MA(250) :	4.15
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	39.2	D(3) :	27.2
RSI	RSI(14): 51.4
52-week	High :	7.92	Low :	1.22

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SER ] has closed below upper band by 26.8%. Bollinger Bands are 71.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.1 - 2.11	2.11 - 2.12
Low:	1.96 - 1.97	1.97 - 1.98
Close:	2.08 - 2.1	2.1 - 2.11

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Mon, 20 Apr 2026
Serina Therapeutics, Inc. (SER) - Minichart

Fri, 17 Apr 2026
Share increase to 125M, 2M-plan reserve sought by Serina (NYSE: SER) - Stock Titan

Thu, 02 Apr 2026
NYSE lets Serina stock keep trading as it works to regain compliance - Stock Titan

Thu, 26 Mar 2026
SER Stock Price and Chart — AMEX:SER - TradingView

Wed, 25 Mar 2026
Serina Therapeutics (NYSE: SER) posts 2025 loss while funding SER-252 trials - Stock Titan

Wed, 25 Mar 2026
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.